Cabinet of Ministers Regulations No. 214, Riga, 21 March 2006 (pr. No 16 22) amendment of the Cabinet of Ministers of 30 November 2004, the Regulation No 974 "Doping Control rules" Issued in accordance with article 6 of the law of sports in the fifth subparagraph of paragraph 4, the draw of the Cabinet of Ministers of 30 November 2004, the Regulation No 974 "Doping Control rules" (Latvian journal, 2004, nr. 192) amendment and put annex 1 as follows: "1. the annex to Cabinet of Ministers of 30 November 2004, the Regulation No 974 Doping substances and doping methods no Doping substances or methods p.k. Group Subgroup Doping substance or method notes 1. S1. Anabolic means S 1.1. Androgenic-anabolic steroids S 1.1 (a). Exogenous anabolic steroids are androgenic 1-androstendiol (5-andros-1-en-3, 17-diol); 1-androstendion (5-andros-1-3.17-Dione-en); bolandiol (19-norandrostenediol); bolasteron; boldenon; boldion (androst-1.4-3.17-Dione-days); calusteron; clostebol; danazol (17-ethynyl-17-hydroxyandros-4-en-[2,3-d] isoxazol); dehydrochlormethyltestosteron (4-hydroxy-chlor-17-17-methylandrost-1.4-day-3-one); desoxymethyltestosteron (17-methyl-5-andros-2-en-17-ol); drostanolon; ethylestrenol (19-nor-17-pregn-4-en-17-ol); fluoxymesteron; formebolon; furazabol (17-hydroxy-androstan-17-methyl-5-[2,3-c] furazan-); gestrinon; 4-hydroxytestosteron (4.17-dihydroxyandros-4-en-3-one); mestanolon; mesterolon; metenolon; methandienon (17-hydroxy-17-methylandrost-1.4-day-3-one); methandriol; methasteron (2, 17-dimethyl-5-androstan-3-one-17-ol); methyldienolon (17-hydroxy-17-methylestr-4.9-day-3-one); methyl-1-testosterone (17-hydroxy-17-methyl-5-andros-1-en-3-one); methylnortestosteron (17-hydroxy-17-methylestr-4-en-3-one); methyltrienolon (17-hydroxy-17-methylestr-4, 9-3, 11-trien-one); methyltestosteron; miboleron; nandrolone; 19-norandrostenedion (estr-4-en-3.17-Dione); norboleton; norclostebol; norethandrolon; oxabolon; oxandrolon; oxymesteron; oxymetholon; prostanozol ([3,2-c] pyrazol-5-17-tetrahydropyranol etioallocholan-); quinbolon; stanozolol; stenbolon; 1-testosterone (17-hydroxy-5-andros-1-en-3-one); tetrahydrogestrinon (18-Homo-pregn-4, 9, 11-17-ol-trien-3-one); trenbolone and other substances with a similar chemical structure or similar biological effect of Exogenous-that body cannot develop natural Endogenous b-S 1.1.-Anabolic Androgenic Steroids Androstenediol (andros-5-en-3, 17-diol); androstenedion (andros-4-en-3.17-Dione); dihydrotestosteron (17-hydroxy-androstan-3-one-5); prasteron (dehydroepiandrosteron, DHEA); testosterone and the following metabolites and isomers: 5-androstan-3, 17-diol; 5-androstan-3, 17-diol; 5-androstan-3, 17-diol; 5-androstan-3, 17-diol; andros-4-en-3, 17-diol; andros-4-en-3, 17-diol; andros-4-en-3, 17-diol; andros-5-en-3, 17-diol; andros-5-en-3, 17-diol; andros-5-en-3, 17-diol; 4-androstenediol (andros-4-en-3, 17-diol); 5-androstenedion (andros-5-3.17-Dione-en); EPI-dihydrotestosteron; 3-hydroxy-androstan-17-5-one; 3-hydroxy-androstan-17-5-one; 19-norandrosterone; 19-norethiocholanolone Endogenous-substance that the body can develop naturally. Doping substances being considered in the sample where androgenic anabolic steroid in the body may develop naturally and that doping substances or its metabolites, or diagnostic markers or other indicators of concentration in the sample is different from that of the concentration normally found in the human body and is associated with the development of the endogenous. If an athlete proves that a doping substance or for its metabolites or markers or other indicators the sample associated with physiological or pathological state, considers that the sample is found doping substances. If, on the basis of reliable analytical methods, laboratory results show that doping substance is of exogenous origin, the doping substances in the sample being considered all deposits in any concentration and the laboratory report on the doping substance found in the sample. In this case, you do not need additional study. If a laboratory reports that the concentration does not differ from that of the concentration normally found in the human body, and reliable analytical methods are not exogenous origin of the substance identified in, but there is a reasonable suspicion, such as steroid profile comparison, about possible doping substances, the anti-doping organization shall arrange for additional studies evaluating any previous test results or arranging further tests to determine the outcome of such physiological or pathological cause or exogenous origin of the substance use of doping. If a laboratory reports that testosterone (T) and (E) the ratio epitestosteron athlete's urine is greater than four to one (4:1), and any reliable analytical method used, the results of the exogenous origin of the substance indicate, you can do additional investigation, assessing the results of previous checks or performing further tests to determine whether the result is a physiological or pathological state, or it had to be of exogenous origin of doping substances. If a laboratory reports, using a reliable analytical methods to determine that the substance is of exogenous origin, do not need additional study, and considered that the sample contains doping substances. If additional reliable analytical method has not been used and is not available for a minimum of three previous test results, the relevant anti-doping organization shall organise at least three athletes for unannounced inspections in three months. If the athlete profile longitudināl these checks do not conform to the norms of physiological Announces doping substances being in the sample. Especially in rare cases of endogenous origin boldenon can be regularly found in the urine in very small concentrations (nanograms per millilitre of (ng/mL)). If the laboratory reports in such low concentrations boldenon and any reliable analytical method used, the results (for example, IRMs) does not specify the origin, exogenous substances can be carried out further inquiries, evaluating the results of previous checks or performing further checks. If additional reliable analytical method has not been used and is not available for a minimum of three previous test results, the relevant anti-doping organization shall organise at least three athletes for unannounced inspections in three months. If the athlete profile longitudināl these checks do not meet the physiological norm, announces doping substances being in the sample. If a laboratory report on the doping substance being in the sample in the case of a 19-norandrostenon, such an opinion is considered to be scientific and reasonable evidence of doping substances for exogenous origin. In such cases, do not require additional study. If the athlete refuses to participate in studies, then consider that a doping substance found in the sample S 1.2. Other anabolic Clenbuterol, zeranol, zilpaterol features and other anabolic features 2. S2. Hormones and similar substances 1. Erythropoietin (EPO).
2. Growth hormone (hGH), insulin-like growth factor (IGF-1 for example), motor growth factor (MGF).
3. the Gonadotrophin (LH; hCG), prohibited in males only.
4. the insulin.
5. Kortikotropīn and other substances with a similar chemical structure or similar biological effect and it atbrīvotājfaktor if a doping substance or its metabolites or markers of diagnostic concentration or other indicator of concentration in the sample is different from that normally found in the human body and which is not associated with endogenous development, this substance and the athlete can prove that this concentration is a physiological phenomenon or pathological consequences, considers that doping substances were found in the samples. If the laboratory using a reliable analytical method, reported that doping substances are exogenous in origin, believes that the sample contains doping substances and doping substances reported being in the sample. If the sample contains other substances with a similar chemical structure or biological effects or diagnostic markers of those hormones, or atbrīvotājfaktor or found other data indicate that the substance is found naturally developed a hormone reported doping substances being samples 3. S3. But all but a-2 agonists-2 agonists, including their D-and L-isomers is an exception, formoterol, salbutamol and salmeterol inhalation terbutalīn use. It requires the use of a therapeutic authorisation. If a laboratory reports on salbutamol (free and glikuronizēt) concentration in urine above 1000 ng/ml (nanograms per millilitre) athlete, who served a therapeutic authorisation, it is regarded as doping substances being samples, unless the athlete can prove that such deposits are the consequences of the use of salbutamol inhalation treatment purposes 4. S4. Features with anti-estrogenic activity aromatase inhibitors, 1 including anastrozol, aminogluthetimid, exemestan letrozol, formestan, testolacton, and other features.
2. Selective estrogen receptor modulator (SERM), including tamoxifen, toremifen raloxifen, and other features.
3. other anti-estrogenic compounds, including fulvestran, cyclofenil, clomiphen and other compounds 5. S5. Masking means diuretic līdzekļi1); epitestosteron, probenecid, alpha-reductase inhibitors (e.g. finasteride, dutasterid); plasma substitutes (such as albumin, dekstrān, hidroksietilciet) and other features.
1) diuretics:

acetazolamid, amilorid, bumetanid, canrenon, chlortalidon, etakrīnskāb, furosemid, indapamid, metolazon, spironolacton, thiazide (e.g. bendroflumethiazid, chlorothiazid, hydrochlorothiazid), triamteren and other substances with a similar chemical structure or similar biological effect (except drosperidon which is not prohibited) therapeutic use permit shall cease to be valid if an athlete's urine contains a diuretic product with other doping substances, which is the highest allowed concentration limits or slightly below 6. M. Doping methods M1. Oxygen transport function improvement a. blood doping, including the origin of any of homologous or autologous blood or heterolog products enter red blood cells.
b. Artificial pegging of oxygen, improvement of transport or delivery, including the chemical, perfluor efaproxiral (RSR13), modified haemoglobin products (e.g. haemoglobin in blood substitutes on the base, mikroinkapsulēt, haemoglobin products) and other methods use M2. Chemical and physical manipulation a. Doping control samples collected during the deterioration of or damage to attempt to change the validity and integrity of the sample. Such action shall be deemed katetrizācij, urine substitution or modification, as well as other manipulations.
(b) Intravenous infusion, medical treatment except for acute cases of the disease 7. S6. Adrafinil, adrenaline1), promoters amfepramon, amiphenazol, benzphetamin, amphetaminil amphetamin, bromantan, carphedon,, cathine2), clobenzorex, cocain, cropropamid, crotetamid, cyclazodon, dimethylamphetamin, ephedrine3), etilamphetamin, etamivan, etilefrin, famprofazon, fenbutrazat, fencamin, fenetyllin, fencamfamin, fenproporex, furfenorex, fenfluramin, heptaminol, isomethepten, levmethamfetamin, meclofenoxat, mefenorex, mephentermin, mesocarb, methamphetamin (D-), methylenedioxyamphetamin, methylenedioxymethamphetamin, p-methylamphetamin, methylephedrine3), methylphenidat, modafinil, nikethamid, norfenefrin, norfenfluramin, octopamin, ortetamin, oxilofrin, parahydroxyamphetamin, pemolin, phenmetrazin pentetrazol, phendimetrazine, phentermine, phenpromethamin,, prolintan, propylhexedrin, selegilin, sibutramine, strychnin, their optical (D-and L-) isomers and other substances with a similar chemical structure or similar biological iedarbību4) 1) adrenaline with a local anesthetic, or local use (e.g., nose, eyes) is not prohibited. 2) is forbidden to use the cathin if its concentration in urine greater than 5 micrograms per millilitre. 3) and methylephedrin use of ephedrin is prohibited, if their concentration in urine is greater than 10 micrograms per millilitre. 4) bupropion, caffein, phenylephrin, pipradol, pseudoephedrine, phenylpropanolamin, synephrin is not considered doping substances 8. S7. Drugs Buprenorphin, dextromoramid, diamorphin (heroin), fentanyl and its derivatives, hydromorphon, methadon, morphin, oxycodon, oxymorphon, pentazocin, pethidin 9. S8. Kanabinoīd in Kanabinoīd (e.g. hashish, marijuana) 10. S9. Glikokortik-steroids All glucocorticosteroid, if use oral, rectal, intramuscular or intravenous injection of. Such a use requires the permission of the therapeutic exception "Prime Minister a. Halloween Health Minister, regional development and local Government Minister m. kučinskis